Predict your next investment

See what CB Insights has to offer

About FLEXcon

FLEXcon Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest FLEXcon News

FLEXcon Announces Global Launch of New PHARMcal® Portfolio for Pharmaceutical Labeling

Aug 24, 2021

High-Performance Materials Engineered to Support a Broad Range of End-Use Applications Download Choose from six PHARMcal® product families to meet the needs of specific application requirements, such as small or large diameter containers, cover-up applications, extreme storage conditions, tamper-evidence, and secondary blood bag labeling. (Photo: Business Wire) Choose from six PHARMcal® product families to meet the needs of specific application requirements, such as small or large diameter containers, cover-up applications, extreme storage conditions, tamper-evidence, and secondary blood bag labeling. (Photo: Business Wire) August 24, 2021 10:00 AM Eastern Daylight Time SPENCER, Mass.--( BUSINESS WIRE )--FLEXcon Company, Inc., an innovator in adhesive coating and laminating, today announced the relaunch of its FLEXcon® PHARMcal® line of track and trace solutions featuring engineered films with exceptional printability, robust adhesion and optimized liners for vials, syringes and ampules, over-the-counter medications, conceal applications, cryogenic labeling, tamper-evidence, and blood bag labeling. The line reduces complexity with a simplified product offering organized by end-use application, making it easier for customers and specifiers to select appropriate products for their intended use. All products are available globally, with several being available from Quick-Ship . These highly engineered, industry-proven solutions feature some of the company’s most high-performing adhesives, with raw material components locked down to ensure consistent quality and performance. “This consolidated product portfolio covers all the bases,” says Lori Bitar, product manager healthcare, FLEXcon. “Moving forward, both label converters and material specifiers can rest assured that the product they choose is appropriate for their application, and that quality and performance will be consistent whether they’re producing a vaccine label, clinical trial label, plasma label or tamper-evident box closure.” All of FLEXcon’s PHARMcal® products have been thoroughly tested for durability and performance. Custom testing in the company’s DAP-certified lab is available for testing against specific application requirements as well as competitive product analysis. Product families include PHARMcal® SUPREME for vials, syringes, and ampules; PHARMcal® OTC for over-the-counter drug labeling; PHARMcal® CONCEAL™ for covering existing labels; PHARMcal® CryoFLEX™ for extreme storage conditions; PHARMcal® TAMPERmark™ for security and counterfeit protection, and PHARMcal® BIOmark for asset tracking of blood materials. About FLEXcon FLEXcon Company, Inc. is a global leader in coated and laminated films and adhesives used as functional components in manufactured goods and in graphics applications. A family-owned company for over 65 years, FLEXcon has provided a collaborative, consultative approach to deliver unique solutions that help customers achieve better business results. FLEXcon is a trusted partner to a wide range of companies, from printers and fabricators to engineers and designers, developing products for existing and emerging markets. Headquartered in Spencer, Mass., the company has operations throughout North America and Europe with distribution worldwide. For more information, visit www.FLEXcon.com , follow FLEXcon on LinkedIn , or call +1-508-885-8200. Contacts

FLEXcon Acquisitions

2 Acquisitions

FLEXcon acquired 2 companies. Their latest acquisition was Arlon Engineered Coated Products on February 18, 2011.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/18/2011

Acquired Unit

1

2/11/2011

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/18/2011

2/11/2011

Investment Stage

Companies

Subscribe to see more

Valuation

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.